Royal Bank of Canada decreased its holdings in shares of China Biologic Products, Inc. (NASDAQ:CBPO) by 0.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 141,774 shares of the biopharmaceutical company’s stock after selling 13 shares during the quarter. Royal Bank of Canada owned about 0.52% of China Biologic Products worth $16,034,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CBPO. Oppenheimer Asset Management Inc. purchased a new stake in shares of China Biologic Products during the first quarter worth $156,000. Nomura Holdings Inc. purchased a new stake in shares of China Biologic Products during the first quarter worth $463,000. Jennison Associates LLC grew its holdings in shares of China Biologic Products by 0.8% during the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 44 shares in the last quarter. AHL Partners LLP purchased a new stake in shares of China Biologic Products during the second quarter worth $842,000. Finally, First Trust Advisors LP grew its holdings in shares of China Biologic Products by 35.9% during the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 3,053 shares in the last quarter. 72.82% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/14/royal-bank-of-canada-reduces-stake-in-china-biologic-products-inc-cbpo.html.

Shares of China Biologic Products, Inc. (CBPO) opened at 80.14 on Friday. The company has a 50 day moving average of $93.10 and a 200-day moving average of $103.09. China Biologic Products, Inc. has a one year low of $79.92 and a one year high of $125.99. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of 20.86 and a beta of 1.75.

China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.05. The firm had revenue of $89.28 million during the quarter, compared to analysts’ expectations of $97.33 million. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The firm’s quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.26 EPS. On average, analysts anticipate that China Biologic Products, Inc. will post $4.95 earnings per share for the current year.

A number of equities research analysts have recently issued reports on CBPO shares. BidaskClub lowered shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Sunday, July 16th. Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a report on Friday, August 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. China Biologic Products currently has a consensus rating of “Hold” and an average target price of $137.50.

China Biologic Products Company Profile

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.